Bone Biologics Corporation (BBLG) News

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form EFFECT - Notice of Effectiveness

Form 424B4 - Prospectus [Rule 424(b)(4)]

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form 8-K - Current report

Bone Biologics Reports Progress With NB1 Clinical Program

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form EFFECT - Notice of Effectiveness